LT3031913T - Naujas antikūnas, atpažįstantis žmogaus tslp receptorių - Google Patents

Naujas antikūnas, atpažįstantis žmogaus tslp receptorių

Info

Publication number: LT3031913T
Authority: LT; Lithuania
Prior art keywords: receptor antibody; novel anti; human tslp; tslp receptor; human
Prior art date: 2013-08-09

Application number

LTEP14833804.9T

Other languages

English (en)

Inventor

Hiromu Sato

Daisuke YAMAJUKU

Kazunori ARAI

Mako OGINO

Original Assignee

Astellas Pharma Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-09

Filing date

2014-08-08

Publication date

2019-05-27

2014-08-08 Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.

2019-05-27 Publication of LT3031913T publication Critical patent/LT3031913T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LTEP14833804.9T 2013-08-09 2014-08-08 Naujas antikūnas, atpažįstantis žmogaus tslp receptorių LT3031913T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2013165676		2013-08-09
PCT/JP2014/071008 WO2015020193A1 (ja)	2013-08-09	2014-08-08	新規抗ヒトｔｓｌｐ受容体抗体

Publications (1)

Publication Number	Publication Date
LT3031913T true LT3031913T (lt)	2019-05-27

Family

ID=52461517

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP14833804.9T LT3031913T (lt)	2013-08-09	2014-08-08	Naujas antikūnas, atpažįstantis žmogaus tslp receptorių

Country Status (28)

Country	Link
US (2)	US9328171B2 (lt)
EP (1)	EP3031913B1 (lt)
JP (1)	JP6380394B2 (lt)
KR (1)	KR102260680B1 (lt)
AR (1)	AR097293A1 (lt)
AU (1)	AU2014303356B2 (lt)
BR (1)	BR112016002743B1 (lt)
CA (1)	CA2920484C (lt)
CY (1)	CY1121678T1 (lt)
DK (1)	DK3031913T3 (lt)
ES (1)	ES2730978T3 (lt)
HR (1)	HRP20190752T1 (lt)
HU (1)	HUE043111T2 (lt)
IL (1)	IL243851B (lt)
LT (1)	LT3031913T (lt)
MX (1)	MX369208B (lt)
MY (1)	MY177098A (lt)
PH (1)	PH12016500237B1 (lt)
PL (1)	PL3031913T3 (lt)
PT (1)	PT3031913T (lt)
RS (1)	RS58696B1 (lt)
RU (1)	RU2689528C2 (lt)
SG (1)	SG11201600935SA (lt)
SI (1)	SI3031913T1 (lt)
TR (1)	TR201906969T4 (lt)
TW (1)	TWI635097B (lt)
UA (1)	UA119328C2 (lt)
WO (1)	WO2015020193A1 (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI836745B (zh) *	2015-12-18	2024-03-21	美商上游生物公司	含有抗人類ｔｓｌｐ受體抗體之醫藥組成物
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
IL299630A (en)	2020-07-06	2023-03-01	Flagship Pioneering Innovations Vi Llc	Antigen binding molecules targeting sars-cov-2
WO2022010912A1 (en)	2020-07-06	2022-01-13	Flagship Pioneering Innovations Vi, Llc	Antigen binding molecules targeting sars-cov-2
AU2021332340A1 (en)	2020-08-26	2023-10-05	Flagship Pioneering Innovations Vi, Llc	Antigen binding molecules targeting sars-cov-2
CN114853888B (zh) *	2021-02-05	2023-11-03	上海洛启生物医药技术有限公司	抗tslp纳米抗体及其应用
CN113069543B (zh) *	2021-06-07	2021-08-06	迈威(上海)生物科技股份有限公司	包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
WO2023028612A2 (en) *	2021-08-27	2023-03-02	Board Of Regents, The University Of Texas System	Anti-tslpr (crlf2) antibodies
CN114028562B (zh) *	2021-11-01	2022-05-24	江苏荃信生物医药股份有限公司	包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的液体制剂
CN117209603B (zh) *	2021-12-02	2024-02-27	北京东方百泰生物科技股份有限公司	一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN116217725B (zh) *	2021-12-02	2023-09-22	北京东方百泰生物科技股份有限公司	一种抗tslp单克隆抗体的纯化方法
AU2023265164A1 (en)	2022-05-06	2024-11-21	Generate Biomedicines, Inc.	Antigen binding molecules targeting sars-cov-2
US12110324B2 (en)	2022-07-22	2024-10-08	Flagship Pioneering Innovations Vi, Llc	Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
JP2025538151A (ja) *	2022-11-07	2025-11-26	アップストリームバイオインコーポレイテッド	抗ヒトｔｓｌｐ受容体抗体を含む医薬組成物及びその使用方法
AR134102A1 (es) *	2023-10-12	2025-12-03	Innovent Biologics Suzhou Co Ltd	ANTICUERPOS ANTI-IL-4Ra Y USOS DE LOS MISMOS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0690132T3 (da)	1993-03-11	2004-04-13	Chemo Sero Therapeut Res Inst	Monoklonalt anti-HIV-antistof
ES2317917T3 (es) *	2000-06-28	2009-05-01	Amgen Inc.	Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US20050249712A1 (en) *	2004-03-23	2005-11-10	The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services	Methods for use of TSLP and agonists and antagonists thereof
KR101383472B1 (ko) *	2006-01-13	2014-04-08	아이알엠 엘엘씨	알레르기 질병 치료를 위한 흉선 간질 림포포이에틴수용체에 대한 항체
JP2010512744A (ja) *	2006-12-14	2010-04-30	シェーリング−プラウ・リミテッド	イヌの胸腺間質リンホポエチンタンパク質およびその使用
EP2170957A1 (en)	2007-06-20	2010-04-07	Irm, Llc	Methods and compositions for treating allergic diseases
CA2713935C (en) *	2008-02-07	2016-11-01	Schering Corporation	Engineered anti-tslpr antibodies
AR082163A1 (es)	2010-07-15	2012-11-14	Hoffmann La Roche	Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US20120020960A1 (en) *	2010-07-26	2012-01-26	Baylor Research Institute	Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
WO2013067051A1 (en) *	2011-11-03	2013-05-10	Merck Sharp & Dohme Corp.	Biomarkers for tslp treatment

2014
- 2014-08-08 LT LTEP14833804.9T patent/LT3031913T/lt unknown
- 2014-08-08 ES ES14833804T patent/ES2730978T3/es active Active
- 2014-08-08 EP EP14833804.9A patent/EP3031913B1/en active Active
- 2014-08-08 WO PCT/JP2014/071008 patent/WO2015020193A1/ja not_active Ceased
- 2014-08-08 MX MX2016001796A patent/MX369208B/es active IP Right Grant
- 2014-08-08 BR BR112016002743-4A patent/BR112016002743B1/pt active IP Right Grant
- 2014-08-08 HU HUE14833804A patent/HUE043111T2/hu unknown
- 2014-08-08 RS RS20190580A patent/RS58696B1/sr unknown
- 2014-08-08 TW TW103127264A patent/TWI635097B/zh active
- 2014-08-08 SI SI201431208T patent/SI3031913T1/sl unknown
- 2014-08-08 PL PL14833804T patent/PL3031913T3/pl unknown
- 2014-08-08 KR KR1020167005884A patent/KR102260680B1/ko active Active
- 2014-08-08 UA UAA201602101A patent/UA119328C2/uk unknown
- 2014-08-08 HR HRP20190752TT patent/HRP20190752T1/hr unknown
- 2014-08-08 DK DK14833804.9T patent/DK3031913T3/da active
- 2014-08-08 JP JP2015530978A patent/JP6380394B2/ja active Active
- 2014-08-08 MY MYPI2016700421A patent/MY177098A/en unknown
- 2014-08-08 CA CA2920484A patent/CA2920484C/en active Active
- 2014-08-08 AU AU2014303356A patent/AU2014303356B2/en active Active
- 2014-08-08 SG SG11201600935SA patent/SG11201600935SA/en unknown
- 2014-08-08 TR TR2019/06969T patent/TR201906969T4/tr unknown
- 2014-08-08 AR ARP140102993A patent/AR097293A1/es active IP Right Grant
- 2014-08-08 RU RU2016107814A patent/RU2689528C2/ru active
- 2014-08-08 PT PT14833804T patent/PT3031913T/pt unknown
2015
- 2015-10-29 US US14/927,007 patent/US9328171B2/en active Active
2016
- 2016-01-28 IL IL24385116A patent/IL243851B/en active IP Right Grant
- 2016-02-03 PH PH12016500237A patent/PH12016500237B1/en unknown
- 2016-04-04 US US15/090,051 patent/US9908941B2/en active Active
2019
- 2019-05-08 CY CY20191100496T patent/CY1121678T1/el unknown

Also Published As

Publication number	Publication date
BR112016002743B1 (pt)	2020-12-08
JP6380394B2 (ja)	2018-08-29
AR097293A1 (es)	2016-03-02
CA2920484A1 (en)	2015-02-12
TW201536806A (zh)	2015-10-01
EP3031913A4 (en)	2017-03-22
TWI635097B (zh)	2018-09-11
RS58696B1 (sr)	2019-06-28
AU2014303356A1 (en)	2016-02-18
CA2920484C (en)	2021-03-30
BR112016002743A2 (pt)	2017-11-21
RU2689528C2 (ru)	2019-05-28
MY177098A (en)	2020-09-05
SG11201600935SA (en)	2016-03-30
US9908941B2 (en)	2018-03-06
MX369208B (es)	2019-10-31
MX2016001796A (es)	2016-04-15
AU2014303356A2 (en)	2017-02-02
TR201906969T4 (tr)	2019-06-21
WO2015020193A1 (ja)	2015-02-12
HRP20190752T1 (hr)	2019-06-14
ES2730978T3 (es)	2019-11-13
EP3031913A1 (en)	2016-06-15
US9328171B2 (en)	2016-05-03
US20160208005A1 (en)	2016-07-21
IL243851B (en)	2019-11-28
AU2014303356B2 (en)	2020-01-02
HUE043111T2 (hu)	2019-08-28
CY1121678T1 (el)	2020-07-31
PL3031913T3 (pl)	2019-08-30
SI3031913T1 (sl)	2019-06-28
DK3031913T3 (da)	2019-05-20
PH12016500237B1 (en)	2019-11-29
JPWO2015020193A1 (ja)	2017-03-02
EP3031913B1 (en)	2019-04-17
KR20160035080A (ko)	2016-03-30
HK1223123A1 (en)	2017-07-21
IL243851A0 (en)	2016-04-21
UA119328C2 (uk)	2019-06-10
US20160046720A1 (en)	2016-02-18
RU2016107814A (ru)	2017-09-14
PT3031913T (pt)	2019-05-31
PH12016500237A1 (en)	2016-05-02
RU2016107814A3 (lt)	2018-06-28
KR102260680B1 (ko)	2021-06-07

Publication	Publication Date	Title
IL243851A0 (en)	2016-04-21	A new anti-human tslp receptor antibody
ZA201808451B (en)	2021-04-28	Anti-fcrh5 antibodies
IL244784A0 (en)	2016-04-21	chimeric antigen receptor
SG11201509361TA (en)	2015-12-30	Novel antibodies
SG11201509609SA (en)	2015-12-30	Chimeric antigen receptor-targeting monoclonal antibodies
EP3083698A4 (en)	2017-08-16	Monoclonal anti-tk1 antibodies
GB201322583D0 (en)	2014-02-05	Antibodies
ZA201601437B (en)	2018-08-29	Antibodies
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
EP3088519A4 (en)	2017-09-13	Novel anti-human bdca-2 antibody
EP2970445A4 (en)	2017-02-22	Humanized anti-n2 antibodies
IL245488A0 (en)	2016-06-30	Anti- ccl17 antibodies
GB201312226D0 (en)	2013-08-21	Improved antibodies
ZA201508081B (en)	2017-09-27	Monoclonal antibody directed against cxcr5
PT2821416T (pt)	2018-12-14	Anticorpo de recetor il-23 anti- humano inovador
SG11201602760YA (en)	2016-05-30	Monoclonal olfml-3 antibodies and uses thereof
GB201318283D0 (en)	2013-11-27	Antibodies